Objective:

To evaluate the efficacy of mezigdomide in combination with carfilzomib and dexamethasone in improving outcomes for patients with relapsed or refractory multiple myeloma (RRMM).

Approach:

• Trial Design: The SUCCESSOR-2 trial randomly assigned 479 adult patients with RRMM to receive either mezigdomide, carfilzomib, and dexamethasone or carfilzomib and dexamethasone alone.
• Treatment Regimen: Patients in the experimental group received mezigdomide at a dose of 1.2 mg on days 1, 8, and 15 of a 28-day cycle, alongside carfilzomib and dexamethasone. The control group received carfilzomib and dexamethasone without mezigdomide.

Key Findings:

• Patients receiving mezigdomide had a median progression-free survival of 18 months compared to 8.3 months for standard treatment.
• 80.2% of patients in the mezigdomide group showed some response to treatment, versus 53.4% in the standard treatment group.
• 26.7% of patients in the mezigdomide group achieved a complete response compared to 8.9% in the standard treatment group.
• Treatment-related side effects were higher in the mezigdomide group (83.7%) compared to standard treatment (56.5%), but were manageable.

Interpretation:

The addition of mezigdomide to standard therapy significantly enhances progression-free survival and response rates in RRMM patients.

Limitations:

• The study's follow-up period was a median of 10.6 months, and long-term outcomes are still being evaluated.
• The trial population may not fully represent all RRMM patients due to prior treatment variability.

Conclusion:

Mezigdomide shows promise as a new standard of care for RRMM, with ongoing studies to further assess its efficacy and safety. ---

Sources:

• Dana-Farber Cancer Institute